Large-scale exploration and analysis of drug combinations

MOTIVATION Drug combinations are a promising strategy for combating complex diseases by improving the efficacy and reducing corresponding side effects. Currently, a widely studied problem in pharmacology is to predict effective drug combinations, either through empirically screening in clinic or pure experimental trials. However, the large-scale prediction of drug combination by a systems method is rarely considered. RESULTS We report a systems pharmacology framework to predict drug combinations (PreDCs) on a computational model, termed probability ensemble approach (PEA), for analysis of both the efficacy and adverse effects of drug combinations. First, a Bayesian network integrating with a similarity algorithm is developed to model the combinations from drug molecular and pharmacological phenotypes, and the predictions are then assessed with both clinical efficacy and adverse effects. It is illustrated that PEA can predict the combination efficacy of drugs spanning different therapeutic classes with high specificity and sensitivity (AUC = 0.90), which was further validated by independent data or new experimental assays. PEA also evaluates the adverse effects (AUC = 0.95) quantitatively and detects the therapeutic indications for drug combinations. Finally, the PreDC database includes 1571 known and 3269 predicted optimal combinations as well as their potential side effects and therapeutic indications. AVAILABILITY AND IMPLEMENTATION The PreDC database is available at http://sm.nwsuaf.edu.cn/lsp/predc.php.

[1]  S. Vilar,et al.  High-Throughput Methods for Combinatorial Drug Discovery , 2013, Science Translational Medicine.

[2]  Hongkang Mei,et al.  Systematic Prediction of Pharmacodynamic Drug-Drug Interactions through Protein-Protein-Interaction Network , 2013, PLoS Comput. Biol..

[3]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[4]  Peter B. McGarvey,et al.  Infrastructure for the life sciences: design and implementation of the UniProt website , 2009, BMC Bioinformatics.

[5]  W. Pearson.  Empirical statistical estimates for sequence similarity searches. , 1998, Journal of molecular biology.

[6]  R. Sharan,et al.  Network-based prediction of protein function , 2007, Molecular systems biology.

[7]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[8]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[9]  Temple F. Smith,et al.  The statistical distribution of nucleic acid similarities. , 1985, Nucleic acids research.

[10]  Ravi Iyengar,et al.  Systems Pharmacology of Adverse Event Mitigation by Drug Combinations , 2013, Science Translational Medicine.

[11]  Panos Macheras,et al.  In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15. , 2002, European Journal of Pharmaceutical Sciences.

[12]  Yonghua Wang,et al.  Deciphering the combination principles of Traditional Chinese Medicine from a systems pharmacology perspective based on Ma-huang Decoction. , 2013, Journal of ethnopharmacology.

[13]  Forest M White,et al.  Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. , 2012, Nature chemical biology.

[14]  M. Gerstein,et al.  A Bayesian Networks Approach for Predicting Protein-Protein Interactions from Genomic Data , 2003, Science.

[15]  A. Skrbo,et al.  [Classification of drugs using the ATC system (Anatomic, Therapeutic, Chemical Classification) and the latest changes]. , 2004, Medicinski arhiv.

[16]  Ayesha Salahuddin,et al.  Combination therapy for hypertension 2013: an update. , 2013, Journal of the American Society of Hypertension : JASH.

[17]  Yong Wang,et al.  Network predicting drug's anatomical therapeutic chemical code , 2013, Bioinform..

[18]  Susan E. Abbatiello,et al.  Erratum: Synergistic drug combinations tend to improve therapeutically relevant selectivity , 2009, Nature Biotechnology.

[19]  Janez Konc,et al.  Binding site comparison for function prediction and pharmaceutical discovery. , 2014, Current opinion in structural biology.

[20]  Xin Chen,et al.  DCDB: Drug combination database , 2010, Bioinform..

[21]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[22]  Charles Boone,et al.  Systems-level antimicrobial drug and drug synergy discovery. , 2013, Nature chemical biology.

[23]  Tao Xu,et al.  Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways , 2013, PLoS Comput. Biol..

[24]  Mark Goadrich,et al.  The relationship between Precision-Recall and ROC curves , 2006, ICML.

[25]  Michael Shannon,et al.  Drug Interactions—A Review , 2005 .

[26]  Alasdair Breckenridge,et al.  Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma , 2008, Nature Reviews Drug Discovery.

[27]  Xing-Ming Zhao,et al.  Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data , 2011, PLoS Comput. Biol..

[28]  J. Lehár,et al.  Systematic discovery of multicomponent therapeutics , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Yoshihiro Yamanishi,et al.  Supervised prediction of drug–target interactions using bipartite local models , 2009, Bioinform..

[30]  Peter J. Park,et al.  Systematic Identification of Synergistic Drug Pairs Targeting HIV , 2012, Nature Biotechnology.

[31]  Philip Resnik,et al.  Semantic Similarity in a Taxonomy: An Information-Based Measure and its Application to Problems of Ambiguity in Natural Language , 1999, J. Artif. Intell. Res..

[32]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[33]  Lu Huang,et al.  Update of TTD: Therapeutic Target Database , 2009, Nucleic Acids Res..

[34]  E. Sausville,et al.  Issues and progress with protein kinase inhibitors for cancer treatment , 2003, Nature Reviews Drug Discovery.

[35]  Byung Sik Kim,et al.  A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy , 2008, Cancer Chemotherapy and Pharmacology.

[36]  R. Sharan,et al.  INDI: a computational framework for inferring drug interactions and their associated recommendations , 2012, Molecular systems biology.

[37]  S. Botton,et al.  Synergysm of voriconazole or itraconazole with other antifungal agents against species of Fusarium. , 2013, Revista iberoamericana de micologia.

[38]  Michael Costanzo,et al.  Systematic exploration of synergistic drug pairs , 2011, Molecular systems biology.

[39]  Sridhar Ramaswamy,et al.  Rational design of cancer-drug combinations. , 2007, The New England journal of medicine.

[40]  C. Steinbeck,et al.  Recent developments of the chemistry development kit (CDK) - an open-source java library for chemo- and bioinformatics. , 2006, Current pharmaceutical design.

[41]  P. Bork,et al.  Network Neighbors of Drug Targets Contribute to Drug Side-Effect Similarity , 2011, PloS one.

[42]  B. Al-Lazikani,et al.  Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.

[43]  Sampsa Hautaniemi,et al.  Fast Gene Ontology based clustering for microarray experiments , 2008, BioData Mining.

[44]  Roded Sharan,et al.  Combining Drug and Gene Similarity Measures for Drug-Target Elucidation , 2011, J. Comput. Biol..

[45]  Shiew-Mei Huang,et al.  Predicting Drug–Drug Interactions: An FDA Perspective , 2009, The AAPS Journal.

[46]  M. Danhof,et al.  Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. , 2005, Pharmacology & therapeutics.

[47]  P. Sorger,et al.  Systems biology and combination therapy in the quest for clinical efficacy , 2006, Nature chemical biology.

[48]  Louis P Garrison,et al.  Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. , 2007, Health affairs.

[49]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[50]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[51]  L. Ellis,et al.  Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. , 2001, Cancer research.

[52]  Yoshihiro Yamanishi,et al.  Predicting drug side-effect profiles: a chemical fragment-based approach , 2011, BMC Bioinformatics.

[53]  Wei Zhou,et al.  Systems pharmacology strategies for drug discovery and combination with applications to cardiovascular diseases. , 2014, Journal of ethnopharmacology.

[54]  Menggang Yu,et al.  Drug–drug interaction prediction: a Bayesian meta‐analysis approach , 2007, Statistics in medicine.

[55]  Dekang Lin,et al.  An Information-Theoretic Definition of Similarity , 1998, ICML.

[56]  Xue Xu,et al.  A Systems Biology Approach to Uncovering Pharmacological Synergy in Herbal Medicines with Applications to Cardiovascular Disease , 2012, Evidence-based complementary and alternative medicine : eCAM.